Your primary signal points to metabolism. Tirzepatide is the most studied dual GIP and GLP-1 agonist with the clearest outcome data. Two vendors reviewed. Take your time.
Dual GIP and GLP-1 receptor agonist, once-weekly injection. Approved for chronic weight management on the strength of SURMOUNT-1 and for type 2 diabetes on SURPASS. Below: what the primary trial data says, what the mechanism actually is, and three caveats the marketing tends to skip.
How often the trial participants hit each weight-loss threshold. Placebo arm is the baseline; 15 mg is the top dose. Numbers marked "approx." are read from the NEJM figures rather than the primary tables.
| Weight-loss threshold | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| ≥5% | 35% | 85% | 89% | 91% |
| ≥10%approx. | 19% | 69% | 78% | 84% |
| ≥15%approx. | 9% | 50% | 64% | 71% |
| ≥20% | 3% | 30% | 50% | 57% |
| ≥25% | 2% | 15% | 32% | 36% |
Tirzepatide binds the GIP receptor with higher affinity than the GLP-1 receptor. At GLP-1 it is a biased agonist favoring cAMP signaling over β-arrestin recruitment, which means slower receptor desensitization than native GLP-1. Translation: it engages GLP-1 signaling without burning out the receptor as quickly.
[5] JCI Insight, 2020GIP receptor activation in adipose tissue improves glucose disposal and lipid handling. Phase 2 data showed insulin sensitivity improvements only partly attributable to weight loss, suggesting a direct tissue effect independent of the appetite pathway.
[5] JCI Insight, 2020A fatty-diacid side chain gives tirzepatide a ~5-day half-life through high-affinity albumin binding. That is why it dosed once weekly rather than daily.
[5] JCI Insight, 2020GI events dominate, heaviest in the first weeks of dose escalation. Pancreatitis incidence stays within placebo range across dose arms when adjudicated.
| Event | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 9.5% | 24.6% | 33.3% | 31.0% |
| Diarrhea | 7.3% | 18.7% | 21.2% | 23.0% |
| Discontinuation from adverse event | 2.6% | 4.3% | 7.1% | 6.2% |
| Pancreatitis (adjudicated) | 0.4% | 0.2-0.4% | 0.2-0.4% | 0.2-0.4% |
In SURMOUNT-4, 82.5% of people who stopped tirzepatide regained at least a quarter of the weight they had lost within a year. Cardiometabolic improvements partially reversed in proportion to regain. Practical read: this is long-term medication, not a course of treatment.
[2] JAMA, 2023In the SURMOUNT-1 body-composition substudy, roughly 74% of weight loss was fat mass and 26% was lean mass. On 15mg the absolute lean-mass loss is 5 to 6 kg. Protein intake and resistance training are not optional on this compound.
[4] Diabetes, Obesity and Metabolism, 2025In a US real-world registry of ~21,000 patients, six-month persistence was 55%. Top reasons for stopping: cost (48%), side effects (15%), shortage or supply gaps (12%). Trial populations are selected. General-population experience is not.
[3] Diabetes, Obesity and Metabolism, 2025“If you are taking these drugs, really pay attention to your protein consumption and your resistance training. That is going to be an important part of being on the right side of that body-composition curve.”
“Dual GIP and GLP-1 agonism is the current state of the art, and muscle loss is the primary near-term concern the next generation of compounds is being designed to offset.”
If any of the below applies, tirzepatide is either off the table or needs a clinician in the loop before a vendor. We are a matchmaker, not a prescriber. Naming this up front is the job.
Not medical advice. This is the shortlist we check against before matching. If anything on it applies to you, the next click is a clinician, not a vendor.
Observational, not prescriptive. The questions people in your goal cluster tend to ask once they are past the quiz.
Your email unlocks the full write-up from our Vendor-Match Agent. Names, pricing, lead times, shipping posture.
Bangkok clinic, peptide-forward practice, ISO/GMP facility, named clinicians with verified credentials.
Vendor name, current pricing, direct contact. No list, no drip.
Bangkok-based direct vendor, COA on request, same-day moto courier in-city, EMS 1 to 2 days domestic.
Vendor name, current pricing, direct contact. No list, no drip.
Here is exactly what lands in your inbox, in the order it lands. No follow-up drip. No upsell sequence. No partner emails.
Quick confirm. We received your metabolism-signal submission. A human is reviewing the Vendor-Match Agent draft right now. Expect the full match within 48 hours.
Two vendors reviewed against the 11-signal rubric. Primary match: [vendor name], [score]/100, [why this one]. Secondary: [vendor name], [score]/100, [in case primary is not right for you]. Pricing posture, direct contact, and the honest tradeoffs. No more emails after this.
That is it. No drip. No list.
The rubric score, what each vendor failed on, and the cheaper alternative if there is one. One email. No list.
We email the match, then stop. No drip. No partner emails.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.